Ogasawara Aiko, Hasegawa Kosei
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan.
Int J Clin Oncol. 2025 Mar;30(3):434-448. doi: 10.1007/s10147-025-02699-0. Epub 2025 Jan 31.
Cervical cancer is the third most common malignant tumor in women worldwide in terms of both incidence and mortality. The field of cervical cancer treatment is rapidly evolving, and various combination therapies are being explored to enhance the efficacy of immune checkpoint inhibitors (ICI) and provide new treatment options for patients at different disease stages. Clinical trials involving immune checkpoint inhibitors are now being conducted following a phase 3 trial with cemiplimab, an ICI, which demonstrated a significant improvement in prognosis in advanced or metastatic cervical cancer patients. These trials include monotherapy and combination therapy with other immune therapies, chemotherapy, or radiation therapy. Furthermore, other approaches for controlling tumors via the immune system, such as therapeutic vaccination for specific tumor antigens or immune cell therapy including chimeric antigen receptor (CAR)-T cell therapy and tumor-infiltrating lymphocytes are being investigated. Ongoing trials will continue to illuminate the optimal strategies for combining these therapies and addressing challenges associated with immune checkpoint failure in cervical cancer. Herein, we conducted a review of articles related to immunotherapy for cervical cancer and describe current treatment strategies for cervical cancer via immunotherapy.
宫颈癌在全球女性恶性肿瘤的发病率和死亡率方面均位居第三。宫颈癌治疗领域正在迅速发展，人们正在探索各种联合疗法，以提高免疫检查点抑制剂（ICI）的疗效，并为不同疾病阶段的患者提供新的治疗选择。在一项使用ICI西米普利单抗的3期试验显示晚期或转移性宫颈癌患者的预后有显著改善之后，目前正在进行涉及免疫检查点抑制剂的临床试验。这些试验包括单药治疗以及与其他免疫疗法、化疗或放疗的联合治疗。此外，正在研究通过免疫系统控制肿瘤的其他方法，例如针对特定肿瘤抗原的治疗性疫苗接种或免疫细胞疗法，包括嵌合抗原受体（CAR）-T细胞疗法和肿瘤浸润淋巴细胞。正在进行的试验将继续阐明这些疗法联合使用的最佳策略，并应对与宫颈癌免疫检查点失败相关的挑战。在此，我们对与宫颈癌免疫治疗相关的文章进行了综述，并描述了目前通过免疫治疗宫颈癌的策略。
